Melanotan II: Why the Tanning Peptide Carries Real Risks
The injectable 'tan jab' is unapproved, broadly active, and linked to mole changes and melanoma in case reports.
Melanotan II is marketed online as a shortcut to a tan without the sun — a peptide you inject to darken your skin. It does, in fact, stimulate pigmentation. But it’s an unapproved drug, sold through unregulated channels, with a side-effect profile that has prompted repeated warnings from dermatologists and regulators. This is one of the clearer cases where the honest answer is caution, not curiosity.
What it does, and why that’s the problem
Melanotan II is an unlicensed synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH), the body’s natural melanocortin signal. It activates melanocortin receptors to stimulate melanin production. Because those receptors do more than control pigment, the drug’s effects spill well beyond skin color — DermNet, the dermatology reference maintained by the New Zealand Dermatological Society, notes documented effects including facial flushing, reduced appetite, nausea and vomiting, and spontaneous erections (priapism) in males occurring one to five hours after injection. That lack of selectivity is why the side effects are broad.
It is not approved for the treatment of any condition. What’s sold online is unregulated, of unknown purity, and self-injected — a combination that compounds every risk below.
Per DermNet, this isn’t a “promising but understudied” compound where the jury is out. It’s unlicensed and largely untested, and warnings have been issued by the US, UK, and several other countries.
The documented concerns
DermNet lists the following among the recognized risks:
| Concern | What’s documented |
|---|---|
| Moles and pigmented lesions | Darkening of existing moles, new moles, and atypical melanocytic naevi |
| Melanoma | Listed as a concern — a potentially serious skin cancer |
| Systemic effects | Flushing, nausea/vomiting, reduced appetite |
| Priapism | Prolonged erection 1–5 hours post-injection — a medical emergency |
| Rare/severe | Rhabdomyolysis (muscle breakdown) and encephalopathy reported |
| Sourcing | Unregulated vials may be mislabeled, contaminated, or misdosed |
The mole and melanoma concern is the one dermatologists weigh most heavily: because the drug stimulates pigment cells, there is genuine worry it could complicate detection of — or accelerate — melanoma. Case reports in the dermatology literature describe new and changing moles, and melanoma, following melanotan use.
Why the warnings persist
Regulators in multiple countries have issued alerts against melanotan products. The pattern is consistent: real pharmacological activity, no approved oversight, and a risk–benefit balance that doesn’t favor cosmetic use.
The takeaway
Melanotan II works in the narrow sense that it tans skin — but “it works” and “it’s safe” are different claims. The compound is unlicensed, broadly active in ways that produce real adverse effects, and tied to specific concerns about pigmented lesions that make dermatological caution more than reflexive conservatism. For a purely cosmetic goal, the evidence points firmly one direction: this is a risk not worth taking.